Status:
COMPLETED
Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients
Lead Sponsor:
Tuen Mun Hospital
Collaborating Sponsors:
The University of Hong Kong
Conditions:
Lupus Erythematosus
Eligibility:
All Genders
18+ years
Brief Summary
A recent randomized controlled trial (RCT) from our group has demonstrated safety and immune response (both humoral and cell-mediated) of the live-attenuated herpes zoster (HZ) vaccine (Zostavax) in s...
Detailed Description
A recent RCT from our group has demonstrated safety and immune response (both humoral and cell-mediated) of the live-attenuated Zostavax in stable SLE patients with a previous history of HZ or varicel...
Eligibility Criteria
Inclusion
- SLE patients who fulfill ≥4 of the 1997 ACR or the 2012 SLICC/ACR criteria for SLE or healthy controls who had participated in the original RCT
- Age ≥18 years
- Having completed the original RCT of HZ vaccine vs placebo
- Having been followed for 5 years since HZ vaccination or placebo injection
- Willing to comply with all study procedures
Exclusion
- Patients who refuse to participate in this long-term extension study
- Patients in the placebo group who have subsequently received HZ vaccination
- Patients who cannot give a written consent (mentally incapable or illiterate)
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04089930
Start Date
June 1 2020
End Date
October 1 2023
Last Update
February 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine, Tuen Mun Hospital
Hong Kong, China, 000